Pyxis Oncology (NASDAQ:PYXS – Get Free Report) and Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.
Profitability
This table compares Pyxis Oncology and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pyxis Oncology | N/A | -215.23% | -112.19% |
| Inovio Pharmaceuticals | N/A | -669.94% | -73.97% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Pyxis Oncology and Inovio Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pyxis Oncology | 1 | 1 | 8 | 0 | 2.70 |
| Inovio Pharmaceuticals | 1 | 1 | 5 | 1 | 2.75 |
Insider & Institutional Ownership
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Pyxis Oncology has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
Earnings & Valuation
This table compares Pyxis Oncology and Inovio Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pyxis Oncology | $13.86 million | 13.48 | -$79.62 million | ($1.41) | -1.59 |
| Inovio Pharmaceuticals | $60,000.00 | 1,981.83 | -$84.95 million | ($0.91) | -1.26 |
Pyxis Oncology has higher revenue and earnings than Inovio Pharmaceuticals. Pyxis Oncology is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
About Pyxis Oncology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
